ClinicalTrials.gg
Drug

Trastuzumab rezetecan clinical trials

studies test it
103
open now
90
in phase 3
18
first study started
2020

How each study uses trastuzumab rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the trastuzumab rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

SHR-A1811
44
Trastuzumab Rezetecan
18
SHR-A1811 for Injection
5
Trastuzumab Rezetecan (SHR-A1811)
5
SHR- A1811
5

In one entry with another drug

Given together, or one or the other

SHR-A1811 & Bevacizumab injection
2

Studies by the year they started

103 studies that test it; most in 2026 (42)

Studies that test trastuzumab rezetecan, by start year
YearStudies
20201
20212
20225
202313
202410
202530
202642

By phase

A phase 1/2 study counts in both.

Phase 1
17
Phase 2
79
Phase 3
18
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 34 · Other 69

Jiangsu HengRui Medicine Co., Ltd. (20) · Fudan University (14) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (13) · Henan Cancer Hospital (7) · Tianjin Medical University Cancer Institute and Hospital (5) · Sun Yat-sen University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Tongji Hospital (3)

Often tested with

Tested in the same studies.

Adebrelimab (18) · Pyrotinib (8) · Famitinib (5) · Tizetatug rezetecan (4) · SHR-1701 (4) · Dalpiciclib (4) · Camrelizumab (4) · Fluzoparib (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Trastuzumab rezetecan is the comparator. A study of two new drugs counts under both.

  • 1Pyrotinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Dec 2030
  • 1Dalpiciclib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Dec 2030
Reaching primary completion within a year · 18, 3 in phase 3

Studies that test trastuzumab rezetecan, phase 3 first.

Studies

Open first, then newest update. How each study uses trastuzumab rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 103

See all 103 studies that test trastuzumab rezetecan →

Given beside what is tested · 9 — trastuzumab rezetecan is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with trastuzumab rezetecan

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call trastuzumab rezetecan · ClinicalTrials.gg INT014248

  • UNII (FDA) 1000BJC8CRTRASTUZUMAB REZETECANOne source FDA
  • NCI Thesaurus C178312Trastuzumab RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.